Christophe Martin
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 10%
- Surgery
- Molecular Biology
- Hepatology top 10%
- Co-authors
- Matti AaproJames CarmichaelStéphane MunierTorben SkovsgaardMarkus BornerTadeusz PopielaDavid RadstoneAmit M. Oza
- Topics
- Colorectal Cancer Treatments and Studies (10 papers)Cancer Treatment and Pharmacology (6 papers)Lung Cancer Treatments and Mutations (3 papers)
- Journals
- Journal of Clinical OncologyBiochemical and Biophysical Research CommunicationsAnnals of Oncology
- Partner nations
- FranceSpainSwitzerland
In The Last Decade
Christophe Martin
13 papers receiving 833 citations
Peers
Comparison fields: 5 of 81
- Oncology 660
- Pulmonary and Respiratory Medicine 309
- Surgery 166
- Molecular Biology 112
- Hepatology 107
Countries citing papers authored by Christophe Martin
This map shows the geographic impact of Christophe Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Martin more than expected).
Fields of papers citing papers by Christophe Martin
This network shows the impact of papers produced by Christophe Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Martin. The network helps show where Christophe Martin may publish in the future.
Co-authorship network of co-authors of Christophe Martin
This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Martin. A scholar is included among the top collaborators of Christophe Martin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Martin. Christophe Martin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 25 | |
| 3 | 28 | |
| 4 | 274 | |
| 5 | 208 | |
| 6 | 179 | |
| 7 | 23 | |
| 8 | A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group). | 14 |
| 9 | 19 | |
| 10 | 13 | |
| 11 | Gemcitabine: safety profile unaffected by starting dose. | 8 |
| 12 | Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. | 16 |
| 13 | 59 | |
| 14 | Chemo-immunotherapy versus chemotherapy in acute myeloid leukemia. Preliminary results. | 3 |
About Christophe Martin
Christophe Martin is a scholar working on Oncology, Hematology and Rehabilitation, having authored 14 papers that have together received 869 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Oncology (660 citations), Hepatology (107 citations) and Pulmonary and Respiratory Medicine (309 citations). Christophe Martin has collaborated with scholars based in France, Spain and Switzerland. Frequent co-authors include Matti Aapro, James Carmichael, Stéphane Munier, Torben Skovsgaard, Markus Borner, Tadeusz Popiela, David Radstone, Amit M. Oza, Stephen Falk and Patrick Schöffski. Their work appears in journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.